Humacyte (HUMA) vs Tenaya Therapeutics (TNYA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Tenaya Therapeutics (TNYA) has outperformed Humacyte (HUMA) over the past year, losing 69.9% versus a loss of 71.3%. Over five years, HUMA leads with a -95.4% price change compared with -97.4% for TNYA. Humacyte is the larger company by market cap ($131.2 million vs $119.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HUMA | TNYA |
|---|---|---|
| Share price | $0.4723 | $0.5334 |
| Market cap | $131.20M | $119.60M |
| 1-day change | -1.19% | -2.40% |
| YTD return | -50.85% | -25.08% |
| 1-year return | -71.29% | -69.86% |
| 5-year return | -95.38% | -97.41% |
| EPS (TTM) | $-0.51 | $-0.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.90 | $2.35 |
| 52-week low | $0.46 | $0.53 |
| Distance from 52-week high | -75.08% | -77.30% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +245.12% | +499.93% |
| Average volume | 6.30M | 2.26M |
| Shares outstanding | 277.80M | 224.23M |
| Employees | 184 | 70 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Humacyte
HUMA stock →Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 184 employees
About Tenaya Therapeutics
TNYA stock →Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 70 employees
HUMA vs TNYA FAQ
Which is bigger, Humacyte or Tenaya Therapeutics?
Humacyte (HUMA) is larger, with a market capitalization of $131.20M compared with $119.60M for Tenaya Therapeutics (TNYA).
Which stock has performed better over the past year, HUMA or TNYA?
TNYA returned -69.86% over the past 12 months, compared with -71.29% for HUMA (price return, excluding dividends). Past performance does not predict future results.
Are Humacyte and Tenaya Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.